Docosyl docosanoate

Endpoint summary

Description of key information

Oral (OECD 423, limit test): LD50 (rat, f) > 2000 mg/kg bw

Study performed with the analogue source substance fatty acids C20-22 (even numbered), C18-22 (even numbered) alkyl esters (EC 701-233-7)

Inhalation (OECD 436): LD50 > 5.7 mg/L air

Study performed with the analogue source substance 2-ethylhexyl oleate (CAS 26399-02-0)

Dermal (OECD 402): LD50 > 2000 mg/kg bw

Study performed with the analogue source substance decyl oleate (CAS 3687-46-5)

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Justification for type of information:

Refer to Analogue Justification provided in IUCLID section 13.

Reason / purpose for cross-reference:

read-across source

Key result

Sex:

female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: Source: EC 701-233-7, NOF, 2008, rat

Interpretation of results:

other: CLP/EU GHS criteria not met, no classification required according to Regulation (EC) No. 1272/2008

Conclusions:

In this acute oral toxicity study in female rats a LD50 value of > 2000 mg/kg bw was determined.

Executive summary:

The acute oral toxicity of the target substance docosyl docosanoate (CAS 17671-27-1) is estimated based on an adequate and reliable in vivo study with an analogue source substance. In this study a LD50 value of > 2000 mg/kg bw was determined in female rats. Therefore, also for the target substance a LD50 value of > 2000 mg/kg bw is taken forward to the hazard assessment and for the determination of the classification. As explained in the Analogue Justification, the differences in molecular structure between the target and the source substances are unlikely to lead to differences in the acute oral toxicity.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Quality of whole database:

The available information comprises an adequate and reliable (Klimisch score 1) study from a source substance with similar structures and intrinsic properties. The selected study is thus sufficient to fulfil the standard information requirements set out in Annex VII, Item 8.5, in accordance with Annex XI, Item 1.5, of Regulation (EC) No. 1907/2006.

Acute toxicity: via inhalation route

Link to relevant study records

Reference

Endpoint:

acute toxicity: inhalation

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Justification for type of information:

Refer to Analogue Justification provided in IUCLID section 13.

Reason / purpose for cross-reference:

read-across source

Duration of exposure:

h

Key result

Sex:

male/female

Dose descriptor:

LC50

Effect level:

> 5.7 mg/L air (analytical)

Based on:

test mat.

Exp. duration:

4 h

Remarks on result:

other: Source: CAS 26399-02-0, SO.G.I.S., 2010

Sex:

male/female

Dose descriptor:

LC50

Effect level:

> 15.4 mg/L air (nominal)

Based on:

test mat.

Exp. duration:

4 h

Remarks on result:

other: Source: CAS 26399-02-0, SO.G.I.S., 2010

Interpretation of results:

other: CLP/EU GHS criteria not met, no classification required according to Regulation (EC) No. 1272/2008

Conclusions:

In this acute inhalation toxicity study in male and female rats a LD50 value of > 5.7 mg/L air after 4 h nose only exposure to an aerosol of the test substance was determined.

Executive summary:

The acute inhalation toxicity of the target substance is estimated based on an adequate and reliable in vivo study with an analogue source substance. In this study a LD50 value of > 5.7 mg/L air after 4 h nose only exposure to an aerosol of the test substance was determined in male and female rats. Therefore, also for the target substance a LD50 value of > 5.7 mg/L air is taken forward to the hazard assessment and for the determination of the classification. As explained in the Analogue Justification, the differences in molecular structure between the target and the source substances are unlikely to lead to differences in the acute inhalatory toxicity.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Quality of whole database:

The available information comprises an adequate and reliable (Klimisch score 1) study from a source substance with similar structures and intrinsic properties. The selected study is thus sufficient to fulfil the standard information requirements set out in Annex VIII, Item 8.5, in accordance with Annex XI, Item 1.5, of Regulation (EC) No. 1907/2006.

Acute toxicity: via dermal route

Link to relevant study records

Reference

Endpoint:

acute toxicity: dermal

Type of information:

read-across from supporting substance (structural analogue or surrogate)

Adequacy of study:

key study

Justification for type of information:

Refer to Analogue Justification provided in IUCLID section 13.

Reason / purpose for cross-reference:

read-across source

Key result

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Remarks on result:

other: Source: CAS 3687-46-5, BASF, 2010

Interpretation of results:

other: CLP/EU GHS criteria not met, no classification required according to Regulation (EC) No 1272/2008

Conclusions:

In this acute dermal toxicity study in male and female rats a LD50 value of > 2000 mg/kg bw was determined.

Executive summary:

The acute dermal toxicity of the target substance is estimated based on an adequate and reliable in vivo study with an analogue source substance. In this study a LD50 value of > 2000 mg/kg bw was determined in male and female rats. Therefore, also for the target substance a LD50 value of > 2000 mg/kg bw is taken forward to the hazard assessment and for the determination of the classification. As explained in the Analogue Justification, the differences in molecular structure between the target and the source substances are unlikely to lead to differences in the acute dermal toxicity.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Quality of whole database:

The available information comprises an adequate and reliable (Klimisch score 1) study from a source substance with similar structures and intrinsic properties. The selected study is thus sufficient to fulfil the standard information requirements set out in Annex VIII, Item 8.5, in accordance with Annex XI, Item 1.5, of Regulation (EC) No. 1907/2006.

Additional information

No data on acute toxicity are available for docosyl docosanoate (CAS 17671-27-1). Adequate and reliable studies performed with analogue source substances are, therefore, used to assess the acute toxicity endpoints (oral, inhalation and dermal).

Acute oral toxicity

The acute oral toxicity of fatty acids C20-22 (even numbered), C18-22 (even numbered) alkyl esters (EC No. 701-233-7) was examined in a study performed according to OECD guideline 423 (limit test) and observing GLP conditions (NOF, 2008, rat). Two groups of three female HanRcc: WIST(SPF) rats each were dosed by gavage with 2000 mg/kg bw of the test substance diluted in polyethylene glycol (PEG 300) as vehicle. All animals were examined for clinical signs within the first 30 min and approx. 1, 2, 3 and 5 h after treatment on Day 1 and once daily during test Days 2 - 15. Body weights were recorded on Day 1 (prior to dosing) and on Days 8 and 15. All animals were necropsied and examined macroscopically. No deaths occurred until the end of the study period. Only ruffled fur was noticed until 3 h post administration in 3/6 animals. No other clinical signs were observed in any animal at any observation time point. The body weight of the animals was within the range commonly recorded for this strain and age. During necropsy, no macroscopic findings were recorded. The LD50 value of fatty acids C20-22 (even numbered), C18-22 (even numbered) alkyl esters after single oral administration to female rats was therefore determined to be > 2000 mg/kg bw.

Acute inhalation toxicity

An acute inhalation study was performed with 2-ethylhexyl oleate (CAS 26399-02-0) according to OECD guideline 436 as acute toxic class method in 3 male and 3 female Crl:WI(Han) rats (SO.G.I.S., 2010). The animals were exposed to an analytical concentration of 5.7 mg/L air of the test substance for 4 h nose only in an exposure chamber based on the flow past nose-only inhalation chamber (Am. Ind. Hyg Assoc. J. 44(12): 923-928, 1983). An aerosol was generated by nebulisation of the test substance by means of a nebuliser (type 950, Hospitak Inc.). No mortality was reported during the exposure or within the 14 days observation period. No clinical signs were noted during exposure. Hunched posture was shown by all animals on Day 2 after exposure. Additionally, body weight gain in males and females was within the range expected for rats of this strain and age used in this type of study. No abnormalities were found at macroscopic post-mortem examination of the animals. The inhalatory 4 h LC50 value of 2-ethylhexyl oleate aerosol in Wistar rats was found to exceed 5.7 mg/L.

Acute dermal toxicity

An acute dermal toxicity study (limit test) was performed with decyl oleate (CAS 3687-46-5) according to OECD guideline 402 (BASF, 2010). Five Wistar rats of each sex received a single dermal application of 2000 mg/kg bw for 24 h under occlusive conditions. Animals were subjected to daily observations and weekly determination of body weight. Macroscopic examination was performed after terminal sacrifice (Day 15). No mortality occurred. Piloerection and/or chromodacryorrhoea were noted in all males on Day 1 and/or 2. No clinical signs of systemic toxicity were noted in females. Scales, scabs, focal erythema were seen in the treated skin area of all females and 3/5 males during the observation. The changes noted in bodyweight gain in males and females were within the range expected for rats used in this type of study and were therefore considered not indicative of toxicity. No abnormalities were found at macroscopic post mortem examination of the animals. In conclusion, the LD50 value of decyl oleate for acute dermal toxicity was found to be > 2000 mg/kg bw.

Justification for classification or non-classification

The available data on acute toxicity via the oral, inhalatory and dermal route of exposure for adequate analogue source substances do not meet the criteria for classification according to Regulation (EC) No. 1272/2008 (CLP). Data are conclusive but not sufficient for classification. Based on an analogue read-across approach, the target substance docosyl docosanoate (CAS 17671-27-1) is, therefore, also not classified for acute toxicity.